therapy group :Reinfusion cell

4 trials

Sponsors

Beijing Boren Hospital

Conditions

Adult refractory/relapsed T lymphoblastic lymphoma/leukemiaRefractory/relapsed CD7 positive lymphomaRefractory/relapsed multiple myelomaRelapsed and refractory multiple myeloma

Early Phase 1

A single-center, open, non-randomized, single-arm clinical trial of autologous CD7-CAR T cells in the treatment of refractory/relapsed CD7-positive lymphoma

RecruitingChiCTR2100042807

Beijing Boren HospitalRefractory/relapsed CD7 positive lymphoma

Start: 2021-01-26Updated: 2021-05-10

Fully human BCMA CAR T cells from related donors combined with allogeneic hematopoietic stem cells: single-center, open, non-randomized, single-arm clinical trial of transplantation for refractory/relapsed multiple myeloma

RecruitingChiCTR2100043251

Beijing Boren HospitalRefractory/relapsed multiple myeloma

Start: 2021-01-28Updated: 2021-06-07

Fully human CD7 CART cells from related donors combined with allogeneic hematopoietic stem cell transplantation for the treatment of refractory/relapsed T lymphoblastic lymphoma/leukemia in adults: single-center, open, non-randomized, single-arm clinical trial

RecruitingChiCTR2100043252

Beijing Boren HospitalAdult refractory/relapsed T lymphoblastic lymphoma/leukemia

Start: 2021-01-27Updated: 2021-06-07

Clinical study of autologous and fully human CS-1-CART in the treatment of relapsed and refractory multiple myeloma

RecruitingChiCTR2100043250

Beijing Boren HospitalRelapsed and refractory multiple myeloma

Start: 2021-01-26Updated: 2021-06-07